Sunday, Sept. 8th Press Briefing

Moderator: Enriqueta Felip/Webcasts at bottom of page

  • Phase 1 Study of Safety, Tolerability, P­­K and Efficacy of AMG 510, a Novel KRASG12C Inhibitor, Evaluated in NSCLC -- R. Govindan
  • Mutations Associated with Sensitivity or Resistance to Immunotherapy in mNSCLC: Analysis from the MYSTIC Trial -- N. Rizvi
  • CheckMate 817: First-Line Nivolumab + Ipilimumab in Patients with ECOG PS 2 and Other Special Populations with Advanced NSCLC -- F. Barlesi
  • KEYNOTE-021: TMB and Outcomes for Carboplatin and Pemetrexed With or Without Pembrolizumab for Nonsquamous NSCLC -- C. Langer
  • Evaluation of TMB in KEYNOTE-189: Pembrolizumab Plus Chemotherapy vs Placebo Plus Chemotherapy for Nonsquamous NSCLC -- M. Garassino followed by Discussion of Langer and Garassino Paper
  • Announcement of JTO Clinical and Research Reports -- A. Adjei